A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis

C. Salvarani, P. Macchioni, I. Olivieri, A. Marchesoni, M. Cutolo, G. Ferraccioli, F. Cantini, F. Salaffi, A. Padula, C. Lovino, L. Dovigo, G. Bordin, C. Davoli, G. Pasero, O. D C Alberighi

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). Methods. Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomized, open, controlled study. The patients were treated with CSA (3 mg/kg/day) or SSZ (2000 mg/day) plus ST, or ST alone (nonsteroidal antiinflammatory drugs, analgesics, and/or prednisone≤5 mg/day). The primary endpoint was the 6 month change in pain. Analyses were on the basis of the intention-to-treat principle. Results. In comparison with both SSZ and ST, there was a statistically significant difference in favor of CSA in terms of the mean changes in the pain score (p

Original languageEnglish
Pages (from-to)2274-2282
Number of pages9
JournalJournal of Rheumatology
Volume28
Issue number10
Publication statusPublished - 2001

Keywords

  • Low dose cyclosporine
  • Psoriatic arthritis
  • Sulfasalazine
  • Symptomatic therapy

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis'. Together they form a unique fingerprint.

Cite this